Cargando…

Sarcopenia and Myosteatosis as Prognostic Markers in Patients with Advanced Cholangiocarcinoma Undergoing Palliative Treatment

Background: Cholangiocarcinoma (CCA) represents the second most common primary liver cancer and is characterized by a very poor outcome, but reliable prognostic markers are largely missing. Sarcopenia, the progressive loss of muscle mass and strength, as well as myosteatosis have been associated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Jördens, Markus S., Wittig, Linda, Heinrichs, Lisa, Keitel, Verena, Schulze-Hagen, Maximilian, Antoch, Gerald, Knoefel, Wolfram T., Fluegen, Georg, Luedde, Tom, Loberg, Christina, Roderburg, Christoph, Loosen, Sven H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509694/
https://www.ncbi.nlm.nih.gov/pubmed/34640358
http://dx.doi.org/10.3390/jcm10194340
_version_ 1784582404570087424
author Jördens, Markus S.
Wittig, Linda
Heinrichs, Lisa
Keitel, Verena
Schulze-Hagen, Maximilian
Antoch, Gerald
Knoefel, Wolfram T.
Fluegen, Georg
Luedde, Tom
Loberg, Christina
Roderburg, Christoph
Loosen, Sven H.
author_facet Jördens, Markus S.
Wittig, Linda
Heinrichs, Lisa
Keitel, Verena
Schulze-Hagen, Maximilian
Antoch, Gerald
Knoefel, Wolfram T.
Fluegen, Georg
Luedde, Tom
Loberg, Christina
Roderburg, Christoph
Loosen, Sven H.
author_sort Jördens, Markus S.
collection PubMed
description Background: Cholangiocarcinoma (CCA) represents the second most common primary liver cancer and is characterized by a very poor outcome, but reliable prognostic markers are largely missing. Sarcopenia, the progressive loss of muscle mass and strength, as well as myosteatosis have been associated with an unfavorable outcome in several clinical conditions, including cancer. Here, we evaluated the prognostic relevance of sarcopenia and myosteatosis using routine abdominal CT (computed tomography) scans in advanced stage CCA patients undergoing palliative treatment. Methods: Routine abdominal CT scans were used to assess the skeletal muscle and the psoas muscle index (L3SMI/L3PMI) at the level of the third lumbar vertebra as radiological indices for sarcopenia as well as the mean skeletal muscle attenuation (MMA) as a surrogate for myosteatosis. Results were correlated with clinical data and outcomes. Results: Using a calculated optimal cut-off value of 71.95 mm(2)/cm, CCA patients with an L3SMI value below this cut-off showed a significantly reduced median overall survival (OS) of only 250 days compared to 450 days in patients with a higher L3SMI. Moreover, the median OS of CCA patients with an L3PMI above 6345 mm(2)/cm was 552 days compared to 252 days in patients with a lower L3PMI. Finally, CCA patients with an MMA above 30.51 Hounsfield Units survived significantly longer (median OS: 430 days) compared to patients with an MMA value below this ideal cut-off (median OS: 215 days). The prognostic relevance of L3SMI, L3PMI, and MMA was confirmed in uni- and multivariate Cox regression analyses. Conclusion: Routine abdominal CT scans represent a unique opportunity to evaluate sarcopenia as well as myosteatosis in advanced CCA patients. We identified the L3SMI/L3PMI as well as the MMA as negative prognostic factors in CCA patients undergoing palliative therapy, arguing that the “opportunistic” evaluation of these parameters might yield important clinical information in daily routine.
format Online
Article
Text
id pubmed-8509694
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85096942021-10-13 Sarcopenia and Myosteatosis as Prognostic Markers in Patients with Advanced Cholangiocarcinoma Undergoing Palliative Treatment Jördens, Markus S. Wittig, Linda Heinrichs, Lisa Keitel, Verena Schulze-Hagen, Maximilian Antoch, Gerald Knoefel, Wolfram T. Fluegen, Georg Luedde, Tom Loberg, Christina Roderburg, Christoph Loosen, Sven H. J Clin Med Article Background: Cholangiocarcinoma (CCA) represents the second most common primary liver cancer and is characterized by a very poor outcome, but reliable prognostic markers are largely missing. Sarcopenia, the progressive loss of muscle mass and strength, as well as myosteatosis have been associated with an unfavorable outcome in several clinical conditions, including cancer. Here, we evaluated the prognostic relevance of sarcopenia and myosteatosis using routine abdominal CT (computed tomography) scans in advanced stage CCA patients undergoing palliative treatment. Methods: Routine abdominal CT scans were used to assess the skeletal muscle and the psoas muscle index (L3SMI/L3PMI) at the level of the third lumbar vertebra as radiological indices for sarcopenia as well as the mean skeletal muscle attenuation (MMA) as a surrogate for myosteatosis. Results were correlated with clinical data and outcomes. Results: Using a calculated optimal cut-off value of 71.95 mm(2)/cm, CCA patients with an L3SMI value below this cut-off showed a significantly reduced median overall survival (OS) of only 250 days compared to 450 days in patients with a higher L3SMI. Moreover, the median OS of CCA patients with an L3PMI above 6345 mm(2)/cm was 552 days compared to 252 days in patients with a lower L3PMI. Finally, CCA patients with an MMA above 30.51 Hounsfield Units survived significantly longer (median OS: 430 days) compared to patients with an MMA value below this ideal cut-off (median OS: 215 days). The prognostic relevance of L3SMI, L3PMI, and MMA was confirmed in uni- and multivariate Cox regression analyses. Conclusion: Routine abdominal CT scans represent a unique opportunity to evaluate sarcopenia as well as myosteatosis in advanced CCA patients. We identified the L3SMI/L3PMI as well as the MMA as negative prognostic factors in CCA patients undergoing palliative therapy, arguing that the “opportunistic” evaluation of these parameters might yield important clinical information in daily routine. MDPI 2021-09-23 /pmc/articles/PMC8509694/ /pubmed/34640358 http://dx.doi.org/10.3390/jcm10194340 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jördens, Markus S.
Wittig, Linda
Heinrichs, Lisa
Keitel, Verena
Schulze-Hagen, Maximilian
Antoch, Gerald
Knoefel, Wolfram T.
Fluegen, Georg
Luedde, Tom
Loberg, Christina
Roderburg, Christoph
Loosen, Sven H.
Sarcopenia and Myosteatosis as Prognostic Markers in Patients with Advanced Cholangiocarcinoma Undergoing Palliative Treatment
title Sarcopenia and Myosteatosis as Prognostic Markers in Patients with Advanced Cholangiocarcinoma Undergoing Palliative Treatment
title_full Sarcopenia and Myosteatosis as Prognostic Markers in Patients with Advanced Cholangiocarcinoma Undergoing Palliative Treatment
title_fullStr Sarcopenia and Myosteatosis as Prognostic Markers in Patients with Advanced Cholangiocarcinoma Undergoing Palliative Treatment
title_full_unstemmed Sarcopenia and Myosteatosis as Prognostic Markers in Patients with Advanced Cholangiocarcinoma Undergoing Palliative Treatment
title_short Sarcopenia and Myosteatosis as Prognostic Markers in Patients with Advanced Cholangiocarcinoma Undergoing Palliative Treatment
title_sort sarcopenia and myosteatosis as prognostic markers in patients with advanced cholangiocarcinoma undergoing palliative treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509694/
https://www.ncbi.nlm.nih.gov/pubmed/34640358
http://dx.doi.org/10.3390/jcm10194340
work_keys_str_mv AT jordensmarkuss sarcopeniaandmyosteatosisasprognosticmarkersinpatientswithadvancedcholangiocarcinomaundergoingpalliativetreatment
AT wittiglinda sarcopeniaandmyosteatosisasprognosticmarkersinpatientswithadvancedcholangiocarcinomaundergoingpalliativetreatment
AT heinrichslisa sarcopeniaandmyosteatosisasprognosticmarkersinpatientswithadvancedcholangiocarcinomaundergoingpalliativetreatment
AT keitelverena sarcopeniaandmyosteatosisasprognosticmarkersinpatientswithadvancedcholangiocarcinomaundergoingpalliativetreatment
AT schulzehagenmaximilian sarcopeniaandmyosteatosisasprognosticmarkersinpatientswithadvancedcholangiocarcinomaundergoingpalliativetreatment
AT antochgerald sarcopeniaandmyosteatosisasprognosticmarkersinpatientswithadvancedcholangiocarcinomaundergoingpalliativetreatment
AT knoefelwolframt sarcopeniaandmyosteatosisasprognosticmarkersinpatientswithadvancedcholangiocarcinomaundergoingpalliativetreatment
AT fluegengeorg sarcopeniaandmyosteatosisasprognosticmarkersinpatientswithadvancedcholangiocarcinomaundergoingpalliativetreatment
AT lueddetom sarcopeniaandmyosteatosisasprognosticmarkersinpatientswithadvancedcholangiocarcinomaundergoingpalliativetreatment
AT lobergchristina sarcopeniaandmyosteatosisasprognosticmarkersinpatientswithadvancedcholangiocarcinomaundergoingpalliativetreatment
AT roderburgchristoph sarcopeniaandmyosteatosisasprognosticmarkersinpatientswithadvancedcholangiocarcinomaundergoingpalliativetreatment
AT loosensvenh sarcopeniaandmyosteatosisasprognosticmarkersinpatientswithadvancedcholangiocarcinomaundergoingpalliativetreatment